Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

[1]  Yan Shi,et al.  Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors , 2015, Molecular Cancer Research.

[2]  James M Ford,et al.  Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Yong,et al.  MicroRNA-22 Suppresses DNA Repair and Promotes Genomic Instability through Targeting of MDC1. , 2015, Cancer research.

[4]  W. Sung,et al.  TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome , 2015, Oncotarget.

[5]  S. Keir,et al.  Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673 , 2015, Pediatric blood & cancer.

[6]  Julian Gehring,et al.  SomaticSignatures: inferring mutational signatures from single-nucleotide variants , 2014, bioRxiv.

[7]  S. Keir,et al.  Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program , 2014, Clinical Cancer Research.

[8]  Adam Kiezun,et al.  Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma , 2014, Proceedings of the National Academy of Sciences.

[9]  H. Walden,et al.  The Fanconi anemia DNA repair pathway: structural and functional insights into a complex disorder. , 2014, Annual review of biophysics.

[10]  J. Squire,et al.  Digital Expression Profiling Identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as Potential Predictive Biomarkers for Neo-Adjuvant Chemotherapy Response in Paediatric Osteosarcoma , 2014, PloS one.

[11]  L. Wiesmüller,et al.  NuMA promotes homologous recombination repair by regulating the accumulation of the ISWI ATPase SNF2h at DNA breaks , 2014, Nucleic acids research.

[12]  Li Ding,et al.  Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. , 2014, Cell reports.

[13]  A. Bouchard-Côté,et al.  PyClone: statistical inference of clonal population structure in cancer , 2014, Nature Methods.

[14]  Yuchen Jiao,et al.  Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas , 2014, Genes, chromosomes & cancer.

[15]  Hao Liu,et al.  RECQ DNA helicases and osteosarcoma. , 2014, Advances in experimental medicine and biology.

[16]  Michael P. Schroeder,et al.  IntOGen-mutations identifies cancer drivers across tumor types , 2013, Nature Methods.

[17]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[18]  A. Vincent-Salomon,et al.  Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.

[19]  G. Mills,et al.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.

[20]  L. Thompson.  Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. , 2012, Mutation research.

[21]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[22]  K. Lindblad-Toh,et al.  Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. , 2011, Bone.

[23]  A. Cleton-Jansen,et al.  Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma , 2010, Genes, chromosomes & cancer.

[24]  M. Dyer,et al.  The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. , 2010, Blood.

[25]  Nuria Lopez-Bigas,et al.  IntOGen: integration and data mining of multidimensional oncogenomic data , 2010, Nature Methods.

[26]  Alun Thomas,et al.  Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. , 2009, American journal of human genetics.

[27]  Jung-Sik Kim,et al.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.

[28]  G. Ottaviani,et al.  The etiology of osteosarcoma. , 2009, Cancer treatment and research.

[29]  Y. Yin,et al.  PTEN: a new guardian of the genome , 2008, Oncogene.

[30]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[31]  A. Ashworth,et al.  Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. , 2007, Human molecular genetics.

[32]  E. Kritikou.  Tumorigenesis: PTEN — a new guardian of the genome , 2007, Nature Reviews Cancer.

[33]  Alan Ashworth,et al.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.

[34]  H. Morreau,et al.  Chromosomal instability in MYH- and APC-mutant adenomatous polyps. , 2006, Cancer research.

[35]  O. Sansom,et al.  Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy. , 2005, Cancer research.

[36]  L. Zhuang,et al.  Characterization of FGFRL1, a Novel Fibroblast Growth Factor (FGF) Receptor Preferentially Expressed in Skeletal Tissues* , 2003, Journal of Biological Chemistry.

[37]  E. Zackai,et al.  Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. , 2003, Journal of the National Cancer Institute.

[38]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  I. Hickson,et al.  DNA helicase deficiencies associated with cancer predisposition and premature ageing disorders. , 2001, Human molecular genetics.

[40]  Y. Ishikawa,et al.  A Case of Werner's Syndrome Associated with Osteosarcoma , 1999, The Journal of dermatology.

[41]  Acknowledgements , 1992, Experimental Gerontology.